Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2020 - 2025)

Historic Long-Term Deferred Tax for Catalyst Pharmaceuticals (CPRX) over the last 10 years, with Q3 2025 value amounting to $48.3 million.

  • Catalyst Pharmaceuticals' Long-Term Deferred Tax fell 44.77% to $48.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.3 million, marking a year-over-year decrease of 44.77%. This contributed to the annual value of $46.0 million for FY2024, which is 2582.64% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $48.3 million for Q3 2025, which was down 44.77% from $50.7 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $50.7 million during Q2 2025, with a 5-year trough of $18.7 million in Q4 2022.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Long-Term Deferred Tax value was $31.4 million (recorded in 2021), while the average stood at $33.1 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Long-Term Deferred Tax crashed by 3033.32% in 2022 and then soared by 9504.7% in 2023.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Long-Term Deferred Tax stood at $23.7 million in 2021, then decreased by 20.94% to $18.7 million in 2022, then skyrocketed by 95.05% to $36.5 million in 2023, then rose by 25.83% to $46.0 million in 2024, then grew by 4.95% to $48.3 million in 2025.
  • Its Long-Term Deferred Tax was $48.3 million in Q3 2025, compared to $50.7 million in Q2 2025 and $48.2 million in Q1 2025.